Metastat Analyst Report Provides Investor Opportunity

NEW YORK, Feb. 17, 2014 /PRNewswire/ -- With the tremendous run in the biotech sector over the last 12 months many have overlooked this micro-cap gem that has terrific upside potential. Metastat, Inc. (OTCQB: MTST) is a life sciences company that provides proprietary platform technologies for the treatment of systemic metastasis. This micro-cap stock is topping the list for many analyst in the coming year.

Metastat has all characteristics that a smart investor would look for in a biotech company. It has short term revenue potential from its platform diagnostic product, which will primarily focus on determining the likelihood of metastasis in patients with breast cancer and should be in the market early 2015. Side-by-side, the company is working rapidly and inexpensively to explore possibility of using the technology for prostate, lung and colorectal cancers. In addition, it has access to a library of targets and drugs with the potential to inhibit metastasis based on the biology and technology the company's work centers around. The underlying technology has been licensed from several premier medical research institutes including MIT and Albert Einstein Medical School.

In October 2013, the company announced that a study of nearly 500 women with breast cancer showed the predictive ability of the company's MetaSite Breast test in detecting mestastic disease.

Metastasis is the spread of a cancer from the primary tumor to distant sites (e.g. liver, lung, bone, brain). Metastatic cancer is almost always fatal. However, not all solid tumors are biologically capable of metastasizing. Only 30-35% of breast cancer and 15-20% of prostate cancers actually spread to other organs, yet a vast majority of these are treated aggressively.

In December 2013, the company announced that it had entered into two separate exclusive worldwide patent and technology license agreements with The Massachusetts Institute of Technology ("MIT") and its David H. Koch Institute for Integrative Cancer Research at MIT and its Department of Biology, Albert Einstein College of Medicine of Yeshiva University, and Montefiore Medical Center. The Agreements cover the use of alternatively spliced mRNA and protein isoform markers for the diagnosis, prognosis and treatment of metastasis in epithelial solid tumor cancers.

With recently awarded patents, further allowances and numerous filings and an experienced management team running both the diagnostic and therapeutic programs, Metastat has advantages that are rarely seen in micro-cap stocks.

An absolutely free and comprehensive analyst report which entails key features global pharmaceuticals industry, product portfolio, market potential, value of the company, analyst summary, price target and analyst recommendation can be viewed in its entirety here: http://bit.ly/MTST-CFA-Report copy and paste to browser may be required

EDITOR NOTES:

1. Metastat, Inc. has authorized Small Cap Street, LLC to use ticker (MTST) in this press release. MTST has not compensated Small Cap Street, LLC or Osman Ghani for the creation or dissemination of this report. Small Cap Street, LLC is the party responsible for issuing the press release and for hosting the full analyst report on smallcapir.com. Osman Ghani, Chartered Financial Analyst, is the author of research report.

2. Information in this release is fact checked and produced on a best efforts basis by Osman Ghani, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].

5.  For any urgent concerns or inquiries, please contact us at [email protected].

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared Small Cap Street, LLC and authored by Osman Ghani, CFA. An outsourced research services provider represented by Osman Ghani, CFA, provided Small Cap Street, LLC this article or report. Small Cap Street, LLC is not entitled to veto, interfere or alter the articles, documents or report once created and reviewed by the outsourced research provider represented by Osman Ghani, CFA.

NOT FINANCIAL ADVICE

Small Cap Street, LLC makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Small Cap Street, LLC is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. Small Cap Street, LLC has been compensated by Hunter Marketing in the amount of seven thousand five hundred dollars for investor relations services. No liability is accepted by Small Cap Street, LLC whatsoever for any direct, indirect or consequential loss arising from the use of this document. Small Cap Street, LLC expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Small Cap Street, LLC does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Small Cap Street, LLC